Recently Featured

What Addiction Medicine Can Teach Us About Dependence on AI

May 11, 2026
Recent discussions in the realm of addiction medicine are shedding light on the growing dependence on artificial intelligence (AI) in various sectors, including pharmaceuticals. As professionals in the industry grapple with the implications of AI integration, the parallels drawn from addiction treatment highlight critical considerations. The debate surrounding addiction often reveals stark divisions among stakeholders,…

Consultation on the Regulation of Gene Therapy Medicinal Products

May 11, 2026
The UK government has initiated a consultation aimed at updating the definition of gene therapy medicinal products, reflecting the latest advancements in scientific research and manufacturing processes. This move underscores the increasing importance of gene therapies in the pharmaceutical landscape, as innovations continue to emerge at a rapid pace. As gene therapies evolve, regulatory frameworks…

Pulsesight Reports Positive Phase 1 Data for PST‑611 in Dry AMD

May 11, 2026
Pulsesight has announced promising results from its Phase 1 clinical trial of PST‑611, a novel therapeutic candidate for dry age-related macular degeneration (AMD). The trial demonstrated early safety and efficacy signals, which are critical as the company prepares to advance into a repeat-dose Phase 2a trial. This progression is particularly significant given the limited treatment…

CSL Sinks to Nine-Year Low on Revenue Warning, $5B Write-Down

May 11, 2026
CSL’s stock has plummeted to its lowest level since early 2017 following a significant downward revision of its full-year revenue guidance by approximately 4%. The company also announced a staggering $5 billion impairment charge, signaling deeper financial challenges ahead. This announcement comes at a critical time when the biopharmaceutical sector is under scrutiny for maintaining…

Ongoing Cases